Encompass Health (NYSE:EHC) Treasurer Edmund Fay Sells 11,937 Shares

Encompass Health Corporation (NYSE:EHC) Treasurer Edmund Fay sold 11,937 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the transaction, the treasurer owned 89,325 shares of the company’s stock, valued at approximately $9,557,775. This represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Encompass Health Price Performance

Shares of EHC traded down $1.87 during trading hours on Tuesday, reaching $106.75. The stock had a trading volume of 1,196,337 shares, compared to its average volume of 1,292,626. The company’s 50-day moving average is $103.94 and its two-hundred day moving average is $113.48. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 1.08. Encompass Health Corporation has a 12 month low of $92.53 and a 12 month high of $127.99. The stock has a market capitalization of $10.61 billion, a PE ratio of 19.27, a PEG ratio of 2.05 and a beta of 0.70.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.17. The company had revenue of $3.09 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.17 earnings per share. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Research analysts expect that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be paid a $0.19 dividend. The ex-dividend date is Wednesday, April 1st. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio is presently 13.72%.

Institutional Trading of Encompass Health

A number of hedge funds have recently made changes to their positions in EHC. Price T Rowe Associates Inc. MD boosted its position in shares of Encompass Health by 24.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock valued at $510,047,000 after buying an additional 948,202 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Encompass Health by 21.7% during the fourth quarter. Wellington Management Group LLP now owns 3,384,877 shares of the company’s stock valued at $359,271,000 after purchasing an additional 603,472 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Encompass Health by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,722,887 shares of the company’s stock worth $289,008,000 after buying an additional 581,812 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Encompass Health by 23.4% during the 3rd quarter. Alliancebernstein L.P. now owns 2,515,878 shares of the company’s stock valued at $319,567,000 after purchasing an additional 476,564 shares during the period. 97.25% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Zacks Research cut Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, Barclays raised their price objective on shares of Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $143.29.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.